Pain reports Phase I data for AD candidate PTI-125

In October, Pain Therapeutics Inc. (NASDAQ:PTIE) reported data from a Phase I trial of Alzheimer's disease candidate PTI-125 in 24 healthy volunteers showing that single oral doses of 50, 100 and 200 mg were well tolerated with no treatment-related adverse events or dose-limiting toxicities (DLTs) reported. Data were presented at the Clinical Trials on Alzheimer's Disease meeting in Boston...